Medicrea Receives FDA Approval for TULIP GENESIS Spinal Fixation System

Recently, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that French biotechnology and medical device company Medicrea International (Medicrea) announced that its spinal fixation system, TULIP GENESIS, has received FDA approval for market launch.

Medicrea, founded in 1990 and headquartered in Lyon, France, is a biotechnology and medical device company. The company is dedicated to developing novel spinal implants through innovative technologies, providing more treatment options for patients with spinal deformities worldwide. Medicrea employs over 200 people and has offices in multiple regions across Europe and the United States. The company was listed on Euronext Paris in July 2006, under the stock ticker symbol ALMED.

Medicrea integrates extensive clinical and scientific data, combining its proprietary software analytics tools with big data and machine learning to develop advanced technologies primarily based on predictive medicine. The company operates a state-of-the-art manufacturing facility in Lyon, where it leverages 3D printing technology to develop and produce patient-specific titanium alloy implants. Medicrea’s products streamline the treatment workflow for spinal disorders, reduce surgical time, and lower the risk of surgical complications.

TULIP GENESIS is an advanced spinal fixation system primarily used to treat conditions such as spinal deformities, offering strong competitiveness in the market. The system comprises a range of spinal implants and surgical instruments, enabling surgeons to perform complex procedures and meet patients’ treatment needs. Integrating innovative medical and manufacturing technologies, TULIP GENESIS is a key component of Medicrea’s proprietary technology platform, UNiD ASI.

Medicrea has developed the UNiD ASI platform by integrating artificial intelligence and predictive modeling with individual patient conditions. Leveraging AI and patient clinical data, the platform supports the development of products including adaptive intelligent spinal implants, patient-specific 3D-printed interbody fusion devices, and spinal fixation systems. UNiD ASI is dedicated to helping surgeons optimize surgical plans, providing personalized medical services to patients, and improving surgical outcomes. This platform pioneers the digital transformation in spine surgery, establishing Medicrea as the only medical technology company capable of enhancing surgical planning and streamlining surgical procedures through intelligent technologies.

Medicrea also boasts a specialized biomedical engineering team, UNiD LAB, which optimizes surgical approaches and develops comprehensive, effective surgical plans through predictive algorithms. The team’s surgical planning capabilities can also predict the specific spinal implants required for individual patients and assess surgery-related risks.

Dr. Chris Ames, Director of Spinal Tumor and Spinal Deformity Surgery at the University of California, San Francisco School of Medicine, stated, “Integrating big data with personalized patient care represents a new frontier in medicine, for which Medicrea’s technologies were developed. These technologies assist surgeons in better managing the entire clinical workflow by providing targeted medical data, thereby facilitating more thorough analysis of surgical plans and ultimately improving clinical outcomes.”

Denys Sournac, President and Chief Executive Officer of Medicrea, stated, “To date, the UNiD ASI platform has been utilized in over 4,000 surgical procedures. The FDA approval of TULIP GENESI marks a significant milestone in the continuous enhancement of the UNiD ASI platform. With the rapid advancement of this platform’s technology, Medicrea is poised to provide surgeons with more advanced solutions for spinal treatment.”

(Compiled by Xu Xiaoxue)